Pipeline
Leading Innovation in OMV Technology
Engineered OMVs from Neisseria meningitidis
At Adjane, we are at the forefront of innovation in outer membrane vesicle (OMV) technology, with a legacy rooted in pioneering work on OMVs derived from Neisseria meningitidis. Leveraging scientific expertise and advanced engineering capabilities from our team, we are developing and advancing multiple prophylactic vaccine programs along clinical development based on our OMV-Vacc platform.
We have molecularly engineered well-characterized Neisseria meningitidis strains – valued for their natural immunostimulatory properties and established safety profile – to optimize their outer membrane vesicles (OMVs). These enhancements improve production yield, reduce reactogenicity, and enable the presentation of heterologous antigens, resulting in a highly versatile and scalable platform for next-generation vaccine development.
Timelines & milestones
With one of our programs already clinically validated and compelling data emerging from challenge studies in additional candidates, our platform is positioned to deliver differentiated vaccine solutions and address critical unmet medical needs.
ADA
AdJane’s Clinically Validated Adjuvant
Information
Adjuvants are vital ingredients used in vaccinology for enhancing the strength and duration of immune protection. AdJane has developed its own adjuvants, ADA-24 for intramuscular administration and ADA-25 for intranasal administration, based on its proprietary OMV-Vacc platform technology. Unlike traditional adjuvants, ADA elicits both cellular (Th1), humoral (Th2), and mucosal (Th17) immune responses, resulting in stronger, more durable immunity. Our proprietary adjuvants are highly versatile and can be incorporated into bacterial or viral concepts, and produced in short timelines at high quality, following GMP requirements.
ADA-25 has shown an excellent safety profile in a Phase 1 clinical trial.
BEA
AdJane’s Engineered Meningococcal OMV Vaccine Candidate Expressing Multiple Gonococcal Antigens for Broad Gonorrhoea Protection
Information
Gonorrhea is a major global public health concern and recognized as a priority pathogen by the WHO. It is one of the most common yet disruptive diseases worldwide, with nearly 100 million cases reported annually and potentially severe health consequences like infertility, neonatal blindness, and increased risk of HIV infection. In addition, Gonorrhea is one of the most urgent antimicrobial resistance (AMR) threats worldwide, as the bacterium Neisseria Gonorrhoeae is rapidly evolving to withstand nearly all available antibiotics. Despite the urgency, vaccine development has long been hindered by Neisseria gonorrhoeae’s ability to evade the immune system and its high genetic variability. Currently, no approved vaccines are marketed, leaving a critical gap in gonorrhea prevention and control.
Epidemiological data suggests that cross-protection against gonorrhoea may be afforded by meningococcal B OMV-based vaccines, which has been associated with reduced gonorrhoea incidence in real-world observational studies. Building on this evidence, we have engineered a vaccine strain by replacing genes encoding four key meningococcal surface antigens with their gonococcal homologues, coupled with modifications to enhance antigen expression. To optimize safety and OMV yield, we introduced targeted genetic deletions alongside antigen replacement, resulting in the production of high levels of safe, immunogenic OMVs enriched with gonococcal antigens.
AdJane is completing 2 animal challenge studies before end of 2025, expecting positive data and progressing into a First-In-Human study.
CARA
Cara – AdJane’s Best-In-Class Quadrivalent HFMD vaccine
Information
Hand Foot and Mouth Disease (HFMD) is one of the most common childhood diseases with prevalence in infants and young children. Caused by multiple enteroviruses, affected
children may experience severe neurological complications such as meningitis, encephalitis and acute flaccid paralysis. The most well-known causative viruses are EV71 and CVA16; however, in recent years coxsackievirus A6 (CVA6) and coxsackievirus A10 (CVA10) have been widely associated with both sporadic cases and outbreaks worldwide. Currently, there are only monovalent inactivated vaccines available against the EV-A71 virus. To match the unmet market need, AdJane is developing a best in class quadrivalent vaccine targeted against all four viruses. This broadly protective vaccine against multiple enteroviruses is set to reduce the disease burden of such outbreaks.